Abstract | BACKGROUND: MATERIALS AND METHODS: Five groups of mice were used including control (without LPS injection), LPS group (LPS injection, 10 mg/kg), and LPS + Scutellarin25, 50, and/or 100 groups (receiving scutellarin orally at different doses of 25, 50, or 100 mg/kg before LPS injection). RESULTS: CONCLUSION: These results indicate that scutellarin could protect against LPS-provoked AKI through restraining inflammation and oxidative stress and maintenance of mitochondrial health and biogenesis which is partly mediated through its regulation of Nrf2/ PPAR-γ/PGC-1α/ NF-kB/TLR4.
|
Authors | Alireza Shahmohammadi, Ravieh Golchoobian, Seyed-Mohamad-Sadegh Mirahmadi, Ali-Mohammad Rousta, Fariba Ansari, Maryam Sharayeli, Tourandokht Baluchnejadmojarad, Mehrdad Roghani |
Journal | Immunopharmacology and immunotoxicology
(Immunopharmacol Immunotoxicol)
Vol. 45
Issue 3
Pg. 295-303
(Jun 2023)
ISSN: 1532-2513 [Electronic] England |
PMID | 36314857
(Publication Type: Journal Article)
|
Chemical References |
- Lipopolysaccharides
- scutellarin
- Toll-Like Receptor 4
- NF-E2-Related Factor 2
- NF-kappa B
- Anti-Inflammatory Agents
|
Topics |
- Mice
- Animals
- Lipopolysaccharides
(toxicity)
- Toll-Like Receptor 4
(metabolism)
- NF-E2-Related Factor 2
(metabolism)
- Oxidative Stress
- NF-kappa B
(metabolism)
- Acute Kidney Injury
(chemically induced, drug therapy, metabolism)
- Anti-Inflammatory Agents
(pharmacology, therapeutic use)
- Mitochondria
(metabolism)
|